I.. INTRODUCTION {#s1}
================

The place, role, and impact of individuals and communities---together, 'the public'---within science, technology, and engineering has, it seems, never before been more obvious, or contested.^[1](#fn1){ref-type="fn"}^ Citizen or public participation^[2](#fn2){ref-type="fn"}^ is a tool of governance which includes various techniques aimed at incorporating the perspectives of publics within science policy and regulation,^[3](#fn3){ref-type="fn"}^ and/or to inform processes of innovation. Many view participation as an unproblematic and important social good when used as part of the regulation of the innovation and implementation of science and technology. Think-tanks like Demos, for instance, have done much to stimulate and promote debates around anticipatory governance and, relatedly, upstream engagement.^[4](#fn4){ref-type="fn"}^ Yet, other commentators have been more critical of such ventures. In particular, some scientists (and bioethicists) have been resistant to the 'democratisation' of policy and research, and a number of social scientists have been vocal in their critiques of the scope and limits of participatory techniques.^[5](#fn5){ref-type="fn"}^

In this article, we consider these issues from a somewhat different (but nevertheless related) vantage point. Drawing on insights from law, regulatory studies, critical theory, and science and technology studies (STS), we explore the ways in which participatory techniques can be understood as technologies themselves (an understanding that brings attention to the techniques and practices that enable symbolic or material change).^[6](#fn6){ref-type="fn"}^ Specifically, we draw attention to how attempts to regulate in the face of uncertain scientific knowledge provide the conditions of possibility for participation. As such, we query the function of participation---what does the technology do?---as well as the norms, values, perspectives, and ultimately, the actual and imagined users that are 'built into' and privileged by it. In other words, we are interested both in how publics^[7](#fn7){ref-type="fn"}^ regulate technologies, and how citizens themselves are regulated through technologies of participation.^[8](#fn8){ref-type="fn"}^

Our case study for this analysis is the European Union\'s (EU\'s) regulation of emerging health technologies, especially nanotechnology (i.e. its nanoregulation).^[9](#fn9){ref-type="fn"}^ One, narrow, definition of nanotechnology is 'the investigation and manipulation of material objects in the 1--100 nanometer range so as to explore novel properties and develop new devices and functionalities that essentially depend on the 1--100 nanometer range'.^[10](#fn10){ref-type="fn"}^ These potentially transformative capabilities are now being applied in a wide range of contexts, including energy, the environment, information, and communication technology, and in the medical sphere. In relation to the latter, the European Medicines Agency, for instance, defines nanomedicine as 'the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often novel physical, chemical and biological properties of materials at nanometre scale'.^[11](#fn11){ref-type="fn"}^

Nano-enabled medical technologies that are emergent or not yet concrete are highlighted in parts of our discussion because they tend to be stressed in EU nanoregulation as an example of a notable field of application. The most likely reason for this is the quotidian use and (revolutionary) potential of nanotechnology in the medical context (highly pertinent to individuals and governments, perhaps especially in post-industrial democratic societies). As such, nanomedicine comprises highly resonant innovative objects (i.e. tools or techniques that can be regarded as novel) and practices (i.e. new scientific disciplines or research agendas) in the public imagination.^[12](#fn12){ref-type="fn"}^ This makes nanomedicine a particularly useful example to pique citizen interest in and engagement with regulatory decision-making. Forging regulation for nanoscience and technology has been undermined by the ambiguity of research and development in this area. That is, the inherent scientific uncertainty about the degree and types of risks nanotechnologies pose, such as to vulnerable recipients/patients, as well as their potential, thwarts exclusive reliance on risk-based regulation that often aims to produce legitimate decisions by using science and focusing on the consequences for safety. This has produced a turn towards exercises in participation that seek to contribute towards regulation through the production of (procedurally if not substantively) legitimate decisions.

We do not attend further to the differences between nanotechnology and nanomedicine, in terms of the nature of the risk and uncertainty about their respective uses, nor do we examine the differences in their regulation. Instead, we focus on participation in the regulation of nanoscience and technology in general. Our reason is simple: as we go on to trace, it is at this broad level that the EU is currently involved, even as medical applications are stressed in the pertinent discourses. Nevertheless, participation in the EU\'s nanoregulation and its more general techno-regulation remain underexplored. This lack of attention is especially striking given the EU\'s increasingly active regulation of emerging and new health technologies, and its growing interest in fostering and governing innovation---including the science of nanotechnology (nanoscience), in the general field of health.^[13](#fn13){ref-type="fn"}^ A focus on participation is especially timely given that the gathering pace of EU nanoregulation means participatory techniques are likely to be developed in the near future.^[14](#fn14){ref-type="fn"}^

Our paper, then, aims to underscore the extent to which, in general, public participation in the EU has been used more to legitimate regulation than to ensure the substantive involvement of citizens in the regulation of science and technology. In essence, participation is a technology to build trust and promote consumption in the marketplace, rather than regulate innovation. Indeed, and as we will later explore, we might speculate as to whether the design of participation---by privileging some kinds of expertise and voices over others---actually *decreases* the impact of citizens on regulation. Furthermore, it is possible that the design of participatory techniques and processes help to produce a mandate for innovation, by leveraging scientific uncertainty to impel innovation which will then reduce this. In this way, we can advance---and proffer some answers to---the question of whether citizens involved in EU participatory exercises are 'regulatory publics' (i.e. publics who can and do impact upon the regulation of science and technology), or whether they are themselves regulated.

Our analytic perspective is built through a variety of literatures, particularly within law, regulatory studies, and STS; accordingly, a broader aim for this article is to contribute to the developing dialogue between law and STS.^[15](#fn15){ref-type="fn"}^ Such scholarship seeks to frustrate the demarcations that may be made between law and science; these divisions serve to deny the normative content of technology and scientific knowledge, and potentially shield innovation from engagement by law.^[16](#fn16){ref-type="fn"}^ We regard it as crucial that these insights be developed and circulated, given the common and potentially dangerous idea that law is unable to 'keep up' with technology---the so-called problem of 'pace' highlighted by Brownsword^[17](#fn17){ref-type="fn"}^---and which links to the potential for the 'rule of technology' as a means of regulating behaviour and social outcomes through design.^[18](#fn18){ref-type="fn"}^

In meeting our aims, in the next section we engage with and synthesise some key insights from law, regulatory studies, critical theory, and STS. In so doing, we hope to animate fresh debate about the scope, limits, and future of public participation at the level of the EU, while also providing a conceptual resource through which positions can be articulated.^[19](#fn19){ref-type="fn"}^ From there, we go on to consider innovation and participation in the EU: what does this look like in general, and how does this play out for nanotechnology specifically? This sets the scene for a more in-depth analysis of public participation in nanotechnology; here, we examine the role played by future uses of nanotechnology, discourses of risk and uncertainty, and practices of 'educating' citizens, in ordering and constituting the machinery of participatory technologies---and thus how they regulate publics and science.

II.. CONCEPTUAL APPROACH {#s2}
========================

The perceived risk of new scientific and technological developments is a central concern especially in relation to the EU, which has met with a crisis of public confidence and legitimacy^[20](#fn20){ref-type="fn"}^ in the wake of high-profile regulatory failures such as the BSE^[21](#fn21){ref-type="fn"}^ crisis of the 1990s. One corollary of this has been a proliferation of debate in regards to what regulation in cases of scientific risk and uncertainty should look like, and how it should be implemented.^[22](#fn22){ref-type="fn"}^ Law and regulatory studies, with their focus on decision-making, are, of course, central to this debate, especially given renewed attention to the salience of the context of scientific uncertainty. This is highlighted in the influential academic analysis provided by Brownsword, who has argued that regulators 'need to tailor their interventions to the perceived risk profile presented by a particular technology'.^[23](#fn23){ref-type="fn"}^ This involves determining such matters as when risk materialises (whether it is when the technology goes wrong or is abused---or works!); the degree of risk (low or high); the kind of harms or hazards to which risk pertains (physical, environmental, social, economic, moral, and political) and the potential for their ranking; and, finally, how risk relates to precaution (whether precaution occurs at risk assessment or somehow operates in risk management).^[24](#fn24){ref-type="fn"}^ In short, the destabilised scientific foundations of decision-making around emerging technologies like nanotechnology present a problem for the production of a risk profile in that so much is unknown and uncertain, and there is little agreement on a range of issues---including how risks 'should be framed, which methodologies should be adopted, \[and\] which values prioritized'.^[25](#fn25){ref-type="fn"}^

Moreover, and as a crucial link to participation, with risk-based approaches undermined but nevertheless still central to the regulation of emergent technologies, such as nanotechnology, 'the legitimacy crisis becomes acute'.^[26](#fn26){ref-type="fn"}^ In such cases, public participation is seen as a key way of achieving accountability and legitimacy.^[27](#fn27){ref-type="fn"}^ Indeed, participation is noted as best occurring from the beginning of technological development. For Mandel, participation at an early stage in innovation when there is 'a high degree of uncertainty and a low degree of attachment to the status quo, can present a *unique opportunity to bring together diverse stakeholders to produce a collaborative governance system* rather than a resource-draining adversarial battle'.^[28](#fn28){ref-type="fn"}^

Nevertheless, irrespective of the precise rationalities^[29](#fn29){ref-type="fn"}^ for participation, including the quelling of contestation through prefiguring what is 'at stake' in discussions, or some sort of input of knowledge and perspectives, early engagement is held to produce smarter regulation.^[30](#fn30){ref-type="fn"}^ Consequently, there is concern for, as Brownsword puts it, the 'general features to be designed in\[to\]'^[31](#fn31){ref-type="fn"}^ participation. Importantly, in the context of the 'bioethical triangle' underpinning regulation---an empowering human rights perspective, a largely restrictive and disempowering dignitarian perspective, and a pragmatic utilitarian perspective^[32](#fn32){ref-type="fn"}^---there is little possibility of substantive agreement, and even proceduralism can reach its limits.

Yet, there is a need to go further here by looking beyond formal proceduralism to explore how regulation in the context of uncertain scientific knowledge provides the conditions of possibility for, and impacts on the design of, participation. That said, public participation in risk regulation is thus not only an important means of steering EU activities and providing a framework for negotiating and governing uncertainty. Participation is also implicated in the fabrication of the boundaries of responsibility and the legitimation of the regulatory process^[33](#fn33){ref-type="fn"}^ and its outcome, i.e. helping foster confidence in and the consumption of innovation.^[34](#fn34){ref-type="fn"}^

Resonant here is work from critical theory, especially that influenced by Foucault. A major insight is the importance of power/knowledge. Knowledge is formulated as encompassing 'the vast assemblage of persons, theories, projects, experiments and techniques that has become such a central component of government'---it is 'the "know how" that makes government possible'.^[35](#fn35){ref-type="fn"}^ In its relation to power, knowledge helps to provide the basis for regulation. This, in turn, is fused with and ordered by a neoliberal political rationality, which seeks to make the subjects of regulation 'complicit' with it.^[36](#fn36){ref-type="fn"}^ In this light, citizen participation in nanoregulation for medical application looks like yet another means of producing docile subjects who actively regulate themselves.^[37](#fn37){ref-type="fn"}^

It is clear that regulation embeds a range of societal concerns, organizational aims, and individual aspirations (as both socio-legal scholars and regulators themselves are of course well aware). However, the target of regulation---science and technology---can itself be understood in these terms, as STS has long shown. This discipline emphasises the importance of investigating the construction, use, and deployment of scientific facts,^[38](#fn38){ref-type="fn"}^ including how knowledge is 'incorporated into practices of state-making, or of governance more broadly'.^[39](#fn39){ref-type="fn"}^ For STS scholars, what we know, how we know it, and what we do are always co-produced.

As with knowledge, so too its material embodiments; sociological and STS research has long shown how technology has a social life of its own. Society is 'built into' artefacts, through ideas concerning how they might and should be used, and how they are eventually implemented.^[40](#fn40){ref-type="fn"}^ In some cases, prospective users are literally included in the design process; in other cases, they are included as imaginaries which reflect innovators\' own social location.^[41](#fn41){ref-type="fn"}^ At the same time, the material world (including technoscientific innovation) impacts powerfully on our experience of our selves and one another; it is constitutive of subjectivity and social life.^[42](#fn42){ref-type="fn"}^ Technologies, then, especially those concerned with health, are 'political machines'^[43](#fn43){ref-type="fn"}^ which become embroiled with and further engender biopolitical debates and campaigns.^[44](#fn44){ref-type="fn"}^

STS research on the ways in which users are configured (or not) by technologies is also germane to recent work within regulatory studies.^[45](#fn45){ref-type="fn"}^ Within this latter literature, analysts are asking hard questions about the accountability of technologies which prescribe user behaviour---and hence shape, constrain, or perhaps even eliminate human agency.^[46](#fn46){ref-type="fn"}^ Work on 'design-based regulation' is (like STS) concerned with what norms, values, virtues, and behavioural options are 'designed-in' and 'designed-out' of technologies, and how these can and commonly do inhibit or prevent action.^[47](#fn47){ref-type="fn"}^ Issues pertaining to oversight and legitimacy, and the place of public participation in innovation, are brought to the fore by Yeung and Dixon-Woods in their examination of design-based regulation and patient safety: 'when rules are embedded in the fabric of design, there is no legal or constitutional obligation on those who identify and design-in the rules to invite participation from *those likely to be affected*, let along take into account other *stakeholder interests*'.^[48](#fn48){ref-type="fn"}^ This may 'obscure normative and programmatic commitments on the part of the designers, allow penetration of commercial and other interests, *reduce professional and public accountability*, \[ *...* \] and *transfer judgments on the tolerability of risk to unaccountable institutions for which there is little transparency or public accountability*'.^[49](#fn49){ref-type="fn"}^

These comments loop back into STS concerns with participation, which---as a consequence of its centrality within innovation policy and practice---has received considerable attention. Many working within STS view participation as a (potential) means of democratising science and technology, helping to ensure responsible and responsive innovation.^[50](#fn50){ref-type="fn"}^ For instance, participation has been figured as a 'technology of humility' that can be used to identify the normative in the technical and as such supplement the dominant 'technologies of hubris' of risk regulation.^[51](#fn51){ref-type="fn"}^ These are complex systems and means of producing stability and economic optimisation, presented as apolitical with the effect of concealing their construction and limitations (such as regulatory distortions and failures).

At the same time, STS has been enduringly critical of forms of participation that seek not to include public perspectives, but rather to induce trust in science and produce acquiescence. Questions are continuously asked regarding *who* shapes the design of participation, *why* this is, *how* it is achieved, and to *what* ends. Such interrogation is propelled by the longstanding concern of STS scholars with policies and practices that figure citizens as ignorant and in need of education. These pluralised and grew in prominence during the 1990s along with widely felt unease regarding advances in (and the potential applications of) genetic engineering/modification. Many influential actors regarded this lack of trust in science as a deficit in knowledge, and various activities were convened in a range of countries in order to address this through education. Such endeavours neglected, however, the fact that individuals know about diverse things in different ways, have a range of expertise, and are often reflexively aware of limitations to their comprehension of particular sociotechnical developments and may actively seek to address these.^[52](#fn52){ref-type="fn"}^ A number of scientists and policy makers have responded to these critiques from STS, and today exercises that were once aimed at increasing the public *understanding of* science are now more frequently viewed as opportunities to promote public *engagement with* science (implying a more 'two-way' dialogue). STS scholars have also come to be increasingly reflective about the ways in which they themselves may contribute to the more problematic aspects of public participation they have traditionally outlined, as they are now enrolled as key actors in the deployment of such participatory technologies.^[53](#fn53){ref-type="fn"}^

Recent STS work on the sociology of expectations and the power of promissory discourse (e.g. statements and debates about the future promise of technologies which do not yet exist) also connects to critiques of (particular modes) of citizen participation.^[54](#fn54){ref-type="fn"}^ Within this literature, ideas about the future have been shown to be 'resources' that can be mobilised by credible individuals and organisations in order to lend further legitimacy to current research practices. Promissory or anticipatory discourses can be regarded as, in a sense, able to 'bring the future into the present'; in so doing, it is rendered as a commodity that can be acted upon in order to literally produce the realities future-orientated discourse describes while constraining or even eliminating the conditions of possibility for others. This may involve the galvanisation of bioethical scholarship to tease out the implications of (prospective) science for society, and hence to provide a kind of regulatory roadmap for innovators to follow in order to expedite the realisation of the futures they have worked so hard to imagine.^[55](#fn55){ref-type="fn"}^ Public participation is a key site where debate around futures is played out, and the kinds of futures made discursively available to citizens engaging in participatory techniques is thus salient since these can, literally, be talked into existence.

Thus far, we have drawn on a range of literature from law, regulatory studies, critical theory, and STS in order to outline some of the political and regulatory logics underpinning and animating public participation in science and technology, and sketched out some of the associated critiques and concerns that have been advanced in regards to participatory techniques. In what follows, we go on to consider how the EU currently fosters and regulates innovation and relates this regime to public participation, before, in turn, examining how that conceptual and normative backdrop is further refined in the broad structures of nanoregulation, and how all of that underpins the design of participatory processes. In tracing the gradual hardening of the conditions of possibility for technologies of participation, we do not seek to propose a specific design for them. Rather, underpinned by a concern for democratic decision-making, we aim to foster a vantage point that seeks to promote discussion on an important yet overlooked aspect of their design: critical reflection on the regulation of publics and the limits on their regulatory potential.

III.. INNOVATION AND PARTICIPATION IN THE EU {#s3}
============================================

A.. Programmatic Level {#s3a}
----------------------

In the context of the EU, (nano)regulation fits within, and is underpinned at the programmatic level, the overarching steer for EU governance, by the 2000 European Council Lisbon Strategy.^[56](#fn56){ref-type="fn"}^ Here research was presented as 'the *driver* for the *production and exploitation of knowledge* \[making it\] above all a *linchpin* in the implementation of the Lisbon strategy to make Europe the *most* dynamic and competitive, *knowledge-based economy* in the world, capable of sustaining economic growth, employment and social cohesion'.^[57](#fn57){ref-type="fn"}^ EU funding of research and development was, and continues to be, seen as integral to the creation of a European Research Area, which aims to 'reinvigorate research in Europe',^[58](#fn58){ref-type="fn"}^ and is linked to the Lisbon Strategy as part the so-called knowledge triangle of research, education, and innovation.^[59](#fn59){ref-type="fn"}^ Importantly, while EU funding is limited by the principle of 'European added value',^[60](#fn60){ref-type="fn"}^ it is directed at enabling discourse between researchers in different Member States (MSs) in order to foster the economic competitiveness of European industry,^[61](#fn61){ref-type="fn"}^ and integration.^[62](#fn62){ref-type="fn"}^

The Lisbon Strategy was subsequently refocused on growth and jobs,^[63](#fn63){ref-type="fn"}^ and in 2010 this was intensified in light of the recent European financial crisis in the European Commission (Commission) 'Europe 2020' strategy for economic growth.^[64](#fn64){ref-type="fn"}^ The focus on optimising the economy by and through the exploitation of knowledge (such as that produced by nanoresearch)^[65](#fn65){ref-type="fn"}^and the propagation of 'knowledge workers\' is also evident in the nanotechnology policy domain, where it is linked to EU funding of innovation through its Framework Programmes (FP). For instance, in the seventh FP, FP7,^[66](#fn66){ref-type="fn"}^ even basic research---including on nanotechnology^[67](#fn67){ref-type="fn"}^---is framed as a driver of growth and understood as signifying a forward march of progress,^[68](#fn68){ref-type="fn"}^ rather than being regarded as a means of increasing knowledge and understanding as an end in itself.^[69](#fn69){ref-type="fn"}^

As such, (nano)science and (nano)technology are embedded within a network that constructs the EU\'s identity, and its narrative about itself (including in terms of what it regulates, how, and why). As we will see, these both seek to reflect and produce public perceptions of nanotechnologies; such perceptions themselves help to sanction---and thus play a role in producing---particular futures where in nanoscience and technology plays a key role.^[70](#fn70){ref-type="fn"}^ In particular, there is an effort to privilege and support the creation and production of innovative nanoproducts in order to enhance the internal market,^[71](#fn71){ref-type="fn"}^ and ultimately the wider project of European integration.

B.. Nanoregulation {#s3b}
------------------

The overarching concerns found at the programmatic level are reflected in discourse on (and constitutive of) nanotechnology.^[72](#fn72){ref-type="fn"}^ For instance, in *Towards a European Strategy for Nanotechnology* (Nanotechnology Strategy), the Commission states: "\[in\] today\'s globalised market, long-term economic success is increasingly dependent on the generation, management and exploitation of knowledge. Investment in R&D is needed to produce knowledge and industrial innovation, \[which\] in turn, needs knowledge to produce wealth. In this way, the loop is closed and fresh private capital can be injected into R&D.^[73](#fn73){ref-type="fn"}^"

Unlocking 'the potential of this knowledge' is also part of the constitution of the EU\'s identity in relation to the rest of the world, as it seeks to project power and generate legitimacy through competitive industries and the cultivation of 'new European *knowledge-based* industries'.^[74](#fn74){ref-type="fn"}^

Ultimately, European 'excellence in nanosciences must finally be translated into *commercially viable products and processes*'. Nanotechnology is presented as being 'one of the most *promising* and rapidly *expanding* fields of R&D to provide *new impetus towards the dynamic knowledge-based objectives of the Lisbon process*'.^[75](#fn75){ref-type="fn"}^ The focus of EU efforts is then to '*ensure the creation and exploitation of the knowledge generated via R&D for the benefit of society*' through a range of actions which include increasing investment in and coordination of research and development, the construction of supporting infrastructure, and the advancement of interdisciplinary education that might result in researchers with, predictably, 'a stronger *entrepreneurial* mindset', and who will work within a socio-technical ecosystem that will provide 'favourable conditions for technology transfer and innovation' in order to 'ensure that European R&D excellence is *translated* into *wealth-generating products and processes*'.^[76](#fn76){ref-type="fn"}^

Notably, and as elaborated below, these rationales are endorsed by the EU\'s harnessing of bioethics. In its *Opinion on the Ethical Aspects of Nanomedicine* (Opinion), the European Group on Ethics in Science and New Technologies (EGE) justifies EU funding and investment into research and development, and, as we shall see, seeks to develop nanoregulation through the leveraging of risk and scientific uncertainty.^[77](#fn77){ref-type="fn"}^ As Harvey and Salter point out, novel science 'gives bioethical expertise access to new governance territory; *bioethical expertise gives sciences access to political acceptability*'.^[78](#fn78){ref-type="fn"}^ Accordingly, we should not be surprised that the EGE has endorsed risk-orientated regulation that seeks to foster and direct, rather than circumscribe, innovation in nanotechnology. Indeed, for biotechnologies in general, the EGE has been shown to be an important means of providing legitimacy and garnering support for innovation.^[79](#fn79){ref-type="fn"}^

The EGE\'s Opinion is supplemented by the 2007 *Code of Conduct for Responsible Nanosciences and Nanotechnologies Research Consultation Paper* (CoC Consultation Paper)^[80](#fn80){ref-type="fn"}^ and 2008 *Code of Conduct for Responsible Nanosciences and Nanotechnologies Research* (Code of Conduct).^[81](#fn81){ref-type="fn"}^ In the CoC Consultation Paper, the Commission states that the resultant code should be 'a basis for international dialogue in this area, where Europe has taken a proactive role'.^[82](#fn82){ref-type="fn"}^ Standard legal foundations^[83](#fn83){ref-type="fn"}^ were combined with principles, norms, and values found in policy documents, including the Nanotechnology Strategy and the EGE\'s Opinion,^[84](#fn84){ref-type="fn"}^ which together are taken to be 'core European values, such as integrity, autonomy, privacy, equity, fairness, pluralism and solidarity'.^[85](#fn85){ref-type="fn"}^ Three key principles of 'precaution, inclusiveness, and integrity'^[86](#fn86){ref-type="fn"}^ were highlighted as necessary to structure the Code of Conduct, with the aim of ensuring that nano-innovation contributes to 'improving human well-being' while also guarding against 'possible threats to human well-being'.^[87](#fn87){ref-type="fn"}^ These points were largely duplicated, albeit in a slightly reconfigured and simplified form in the Code of Conduct as 'general principles' (some of which are highlighted in the next section): meaning (explained as 'comprehensible to the public' and respectful of 'fundamental rights and be conducted in the interest of the well-being of individuals and society'^[88](#fn88){ref-type="fn"}^), sustainability, precaution, inclusiveness, excellence, innovation, and accountability.^[89](#fn89){ref-type="fn"}^

The Code of Conduct is an important technology through which the EU produces its identity: specifically, it presents EU innovation as rational and legitimate, while also rendering it more governable (since a deviation from the code comes with an implicit or explicit threat of sanction).^[90](#fn90){ref-type="fn"}^ The Code of Conduct is also a means by which the EU produces and exercises power---and, indeed, further contributes to the fostering of innovation, since 'the very process of deliberating about codes' help to 'build shared agendas' and enable 'future co-ordinated initiatives'.^[91](#fn91){ref-type="fn"}^ At the same time, the kinds of bioethical discourses constitutive of codes of conduct are 'capable of legitimizing the regulatory polices necessary for maintaining public trust'.^[92](#fn92){ref-type="fn"}^ Together, the CoC Consultation Paper and Code of Conduct underscore our points that regulation in the EU is designed to foster research, development and economic optimisation, orientated around risk, and animated through expectations about positive sociotechnical futures enabled by innovative science and technology. Overall, this is a means of presenting the EU as a legitimate, accountable body that is an international leader in socially robust innovation. Yet, as we go on to explain this attempt at producing legitimacy is undermined by the design of publics in nanoregulation.

C.. Participation in Science and Technology {#s3c}
-------------------------------------------

While the importance of ensuring the 'creation and exploitation of the knowledge generated via R&D for the *benefit of society*'^[93](#fn93){ref-type="fn"}^ is noted by the Commission, those benefits are largely undefined. Given the predominant focus of the EU on economic optimisation, it is plausible that societal benefit is seen largely to emerge from this (if it is not directly reduced to it). Participation is tacked onto these actions through rather imprecise language that highlights the need to 'integrate *societal considerations* into the R&D process at an *early stage*'.^[94](#fn94){ref-type="fn"}^ However, exactly why this should be is commonly unspecified. Furthermore, if participation may be deemed to have the potential to decelerate innovation, it would---under the normative regime the EU has built for itself---be more sensible to minimise the scope and impact of participatory techniques. It is with this in mind that social scientists noted in *Taking European Knowledge Society Seriously* that any 'loss of potential economic competitiveness is invoked as almost a 'state of emergency', such that efficiency overrides the slower and more cumbersome application of democratic principles'.^[95](#fn95){ref-type="fn"}^

The EU, then, has not formally institutionalised participation in or around the assemblage of actors and organisations regulating and constituting techno- and especially nano-science in Europe. While a range of initiatives such as citizen panels exist, the EU\'s more general weak legal commitment to participation is mirrored in its approach to nanoregulation and innovation. The weak legal foundations are found in, for example, the EU\'s Treaties^[96](#fn96){ref-type="fn"}^ and, importantly in the nanotechnology sphere, one of the standard legal foundations for the Code of Conduct 'general principles' noted above, the Aarhus Convention (1998). Although potentially important for the general field, this instrument focuses on supporting participation to address just environmental impacts and as such seems rather limited in relation to medical applications as it fails to address the full range of concerns they might raise.^[97](#fn97){ref-type="fn"}^ Unsurprisingly then, participation is constructed more through (legally) non-binding policy statements.^[98](#fn98){ref-type="fn"}^ These include *European Governance*,^[99](#fn99){ref-type="fn"}^ which called for openness, transparency and enhanced public participation throughout the process of science-based decision making,^[100](#fn100){ref-type="fn"}^ in order to reinforce accountability, and engender (or restore) public trust and legitimacy. This is especially orientated towards areas of risk and scientific uncertainty, such as nanotechnologies. Yet, even as participation has an underspecified regulatory role, the focus on innovation and the installation of a neoliberal orientation in EU regulation limits and implicitly steers the use of participation towards promoting rather than challenging or shaping scientific and technological research trajectories.^[101](#fn101){ref-type="fn"}^

Another key document, *Science and Society Action Plan*,^[102](#fn102){ref-type="fn"}^ contains similar themes to those apparent within *European Governance* and other documents.^[103](#fn103){ref-type="fn"}^ Supported by Public Understanding of Science (PUS) techniques that actively seek to measure public opinion and knowledge, such as the Eurobarometer,^[104](#fn104){ref-type="fn"}^ the focus is on the promotion of scientific education and culture, public awareness, science education, and the development of responsible polices that win wider confidence; for instance, through 'a structured dialogue' between scientists, industry, and civil society and the establishment of a Commission-led Stakeholders\' Forum. Yet, at the same time, public involvement continues to be figured in terms of a 'deficit model' within which participation is a means of (much needed) education for citizens who are seen as deficient in their knowledge about science.^[105](#fn105){ref-type="fn"}^ Such education may also more widely involve various other actors and institutions, such as media, researchers, universities, and industry. Overall, in general technologies of participation in the EU have tended to be used more to legitimate regulation, than ensure the (substantive) involvement of citizens in regulatory and priority setting in innovation.^[106](#fn106){ref-type="fn"}^

Having considered the general conceptual and normative backdrop for EU nanoregulation and its relationship to participation, in the next section we proceed to highlight the norms, values, and sociotechnical imaginaries immanent to the discourses. In doing so we ask whether the publics constructed are regulatory or regulated. We work in broad brush strokes rather than close detail in order to highlight examples that are indicative of the broader picture, focusing in particular on documents making forward-looking statements (especially the Nanotechnology Strategy^[107](#fn107){ref-type="fn"}^) and those considering codes of conduct.^[108](#fn108){ref-type="fn"}^

IV.. THE PUBLIC IN EU NANOREGULATION {#s4}
====================================

A.. Anticipating (Certain) Nano-futures {#s4a}
---------------------------------------

It is, we believe, fair to say that expectations about the future are of paramount importance when considering the approach of the EU towards nanotechnology, including its medical applications. Indeed, in the Nanotechnology Strategy, nanotechnology is noted as '" horizontal", " key" or "enabling" since it can pervade virtually all technological sectors...and is *expected to lead to innovations that can contribute towards addressing many of the problems facing today\'s society*'.^[109](#fn109){ref-type="fn"}^ Medical applications, noted earlier, are also regarded by the EU as one promising problem area, and are seen as including: "miniaturised diagnostics that *could be* implanted for *early diagnosis* of illness. Nanotechnology-based coatings *can improve* the bioactivity and biocompatibility of implants. Self-organising scaffolds *pave the way* for new generations of tissue engineering and biomimetic materials, with the *long-term potential* of synthesising organ replacements. Novel systems for targeted drug delivery are *under development* and recently nanoparticles *could be* channelled into tumour cells in order to *treat* them, e.g. through heating.^[110](#fn110){ref-type="fn"}^"

In light of such expectations, the integration of 'societal considerations into the R&D process at an *early stage*'^[111](#fn111){ref-type="fn"}^ is one action for policy. As such, apparently in an effort to convince scientific experts and regulators, it is 'in the common interest to *adopt a proactive stance* and *fully integrate societal considerations* into the R&D process, *exploring its benefits, risks and deeper implications for society*'. Regulatory publics are seemingly encouraged---especially since this process 'needs to be carried out *as early as possible*'.^[112](#fn112){ref-type="fn"}^ This is echoed by the EGE, which configures participation in relation to risk as 'societal dialogue' and notes the need for participation 'public concerns are approached and discussed *from the beginning*'.^[113](#fn113){ref-type="fn"}^ Moreover, in the Code of Conduct, the general principle of 'inclusiveness' means that 'research activities should be guided by the principles of *openness to all stakeholders*, transparency and respect for the legitimate right of access to information. It should allow the *participation in decision-making processes* of all stakeholders involved in or concerned'.^[114](#fn114){ref-type="fn"}^

However, 'the complex and invisible nature of nanotechnology presents a *challenge for science and risk communicators*'.^[115](#fn115){ref-type="fn"}^ In other words, as elaborated below, publics need to be educated if they are to be enrolled in regulation. This is to be achieved, in part, by 'governing anticipation', which indicates participation is a technology for the regulation of public expectations even as hopes and benefits are articulated: "Without a serious communication effort, nanotechnology innovations could face an unjust negative public reception. An effective two-way dialogue is indispensable, whereby the general publics\' views are taken into account and may be seen to influence decisions concerning R&D policy. The public trust and acceptance of nanotechnology will be crucial for its long-term development and allow us to profit from its potential benefits. It is evident that the scientific community will have to improve its communication skills.^[116](#fn116){ref-type="fn"}^"

Of course, this implies a role for regulatory publics through dialogue about nanotechnology development. As Borup and colleagues point out, expectations are 'first and foremost "constitutive" or "performative" in *attracting* the interest of necessary allies (various actors in innovation networks, investors, regulatory actors, *users* and so on)'.^[117](#fn117){ref-type="fn"}^ Unsurprisingly then, the expectations associated with nanotechnology propel investment in this area, with public (and even private) funding endorsed by the EGE.^[118](#fn118){ref-type="fn"}^ Perhaps, especially in regards to medical applications, there is also, as Doubleday notes, a concomitant expansion in social and ethical engagement and debate.^[119](#fn119){ref-type="fn"}^ In particular, nanoregulation brings to the fore different and contested ideas of not just the technology to be brought into being and regulated, but also how it will fit into society, and how different notions of human dignity and morality will be defined, perpetuated, and perhaps reshaped.^[120](#fn120){ref-type="fn"}^

At the same time, however, visions of the medical and economic import of the technology regulate publics through defining what is 'at stake', and by implication the citizens included as stakeholders^[121](#fn121){ref-type="fn"}^ in participatory techniques. For instance, the focus on hope, benefit, and similar expectations might support and privilege---or, in other words, design-in---the articulation of human rights and utilitarian-based ethics, respectively,^[122](#fn122){ref-type="fn"}^ while limiting the discursive space for---and implying the design-out of---a dignitarian ethic. In any case, the limited discursive space undermines procedural epistemic integration of more pessimistic or, perhaps more accurately, contrary voices in participatory techniques. As a consequence, such voices might be constrained, or even squeezed out and silenced.^[123](#fn123){ref-type="fn"}^ In short, the focus on hope and other positive expectations enrols, and prioritises the inclusion of and the voicing of claims by, those individuals and groups who actively campaign towards, for example, public funding or research that addresses their concerns and supports the development of nano-enabled 'hope technologies'.^[124](#fn124){ref-type="fn"}^ Recognised in diverse studies from various disciplines, such individuals and groups include those whose biology or medical status^[125](#fn125){ref-type="fn"}^ renders them particularly interested in innovation for the treatment of their conditions.^[126](#fn126){ref-type="fn"}^

In relation to 'accountability', the Code of Conduct states '\[*r*\]*esearchers and research organisations* should remain accountable for the social, environmental and human health impacts that their N&N \[nanoscience and nanotechnology\] research may impose on present and future generations'.^[127](#fn127){ref-type="fn"}^ Moreover, Borup and colleagues note how promissory discourses are implicated 'in *defining roles* and in *building mutually binding obligations and agendas*'.^[128](#fn128){ref-type="fn"}^ That is, participation as part of hopeful scientific citizenship is also a technique of responsibilisation (i.e. a means of making citizens feel responsible) that helps further regulate publics and mediate and limit EU accountability.^[129](#fn129){ref-type="fn"}^ Even as some non-expert stakeholders\' voices are privileged, they are implicated in taking (part of) the blame in the event of failure, if and when some hopes are dashed and some fears are realised.^[130](#fn130){ref-type="fn"}^ This helps to limit and legitimate regulatory objectives and options, and maintain legitimacy in the event of failure.^[131](#fn131){ref-type="fn"}^

B.. Engaging with Risk {#s4b}
----------------------

Anticipation and expectation are central to, and indeed constitutive of, nanoscience and technology.^[132](#fn132){ref-type="fn"}^ Yet, the risk profile of nanotechnology is likewise salient, and, as noted above, key to how it is regulated. Indeed, risk is central in the leveraging of uncertainty to support nanoregulation,^[133](#fn133){ref-type="fn"}^ bringing nanotechnological futures into the present,^[134](#fn134){ref-type="fn"}^ and further configuring the conditions of possibility for participation.^[135](#fn135){ref-type="fn"}^ The 'awareness' of the 'general public' about nanotechnology is identified as growing, regarded as evidenced through requests for information and the raising of safety concerns.^[136](#fn136){ref-type="fn"}^

While much discourse around nanotechnology is promissory, this also includes negative expectations such as anxiety about sociotechnical change and fears about safety.^[137](#fn137){ref-type="fn"}^ It is this, then, which provides a basis for public engagement in risk regulation. For instance, as is asserted in the CoC Consultation Paper: "Good governance of nanosciences and nanotechnologies implies an open and transparent *public dialogue* addressing possible risks and realistic expectations. The Code of Conduct could *address the requirement of explicit consideration of the limits of knowledge and control over the development of the technology*. It could also highlight the *need to avoid economic risk* and *inappropriate public investments* in nanotechnology.^[138](#fn138){ref-type="fn"}^"

Furthermore, as noted in the Nanotechnology Strategy: "Some people criticise the scientific community for being too far removed from the mechanisms of democracy with a lack of public understanding, public perception of risks versus benefits, and *public participation and possibility of control*. While the potential applications of nanotechnology can improve our quality of life, there may be some risk associated with it, as with any new technology---this should be openly acknowledged and investigated. At the same time *the public\'s perception of nanotechnology and its risks should be properly assessed and addressed*.^[139](#fn139){ref-type="fn"}^"

Accordingly, the Nanotechnology Strategy notes that nanotechnology 'must be *developed in a safe and responsible manner*. Ethical principles must be adhered to and potential health, safety or environmental risks scientifically studied, also in order to *prepare* for possible regulation'.^[140](#fn140){ref-type="fn"}^

Within this discursive arena, public engagement can be read as a means of risk communication,^[141](#fn141){ref-type="fn"}^ resonant with the call to 'govern anticipation' noted above. The overriding focus on safety is reinforced by the EGE, which outlines other ethical questions pertaining to nanotechnology,^[142](#fn142){ref-type="fn"}^ and asks: 'how do we check that, because of their greater capacity to pass through biological systems ... nanodevices designed for drug delivery would not induce negative side-effects for patients\[?\]'.^[143](#fn143){ref-type="fn"}^ Overall, then, the focus is on a technical model of risk, including a narrow range of matters 'at risk', such as 'health and environmental risks'.^[144](#fn144){ref-type="fn"}^ This ensures the privileging of expert interpretation of scientific data and their provision of 'risk knowledge', which regulates publics as it implicitly reduces---and designs-out---the importance of their (non-expert) participation. Revealingly, risk, instantiated as safety, is the prime concern for dialogue prefigured by 'information sharing',^[145](#fn145){ref-type="fn"}^ and directed at 'success'.^[146](#fn146){ref-type="fn"}^

Precaution might provide additional space for participation and regulatory publics through explicit reference to societal concerns and norms.^[147](#fn147){ref-type="fn"}^ As noted above, precaution is mentioned in (for example) the Code of Conduct as a key general principle, and again in the Nanotechnology Strategy: 'The Precautionary Principle, as used up to now, could be applied in the event that *realistic and serious risks are identified*'.^[148](#fn148){ref-type="fn"}^ Similarly, the EGE notes 'uncertainties and knowledge gaps associated with new nanotechnology-based diagnostics, therapies and preventive measures should be identified. These uncertainties need to be characterized and measures have to be developed in order to reduce them as far as possible'.^[149](#fn149){ref-type="fn"}^ However, in both of these examples, precaution is marginalised to risk management. In effect, there is, as Brownsword puts it, 'no risk to manage'.^[150](#fn150){ref-type="fn"}^ This has the effect of further limiting the potential for regulatory publics, in that publics themselves are regulated by virtue of the narrowness of discursive space within which they could feasibly operate. This presumably reinforces the bias, noted above, towards inclusion and voicing of certain ethical stances (over and above others). Indeed, as Brownsword remarks, once a 'technology has been pronounced safe, or at any rate not demonstrably unsafe, the *weight of "expert" scientific opinion makes it difficult for dissenting voices to be heard*'.^[151](#fn151){ref-type="fn"}^ The increasingly limited scope for participation, in spite of calls to integrate 'the societal dimension'^[152](#fn152){ref-type="fn"}^ in risk regulation and an 'inclusive approach'^[153](#fn153){ref-type="fn"}^ to responsible research, works to reinforce the boundaries of responsibility and accountability: citizen participation in the regulation of risk can thus be regarded as an attempt to produce shared responsibility in the event of failure.^[154](#fn154){ref-type="fn"}^

C.. 'Engagement' as 'Education' {#s4c}
-------------------------------

These concerns are followed by an apparent extension of risk to encompass broader yet still underspecified '\[s\]ocietal impacts' that 'need to be examined and *taken into account. Dialogue with the public is essential to focus attention on issues of real concern rather than "science fiction" scenarios*'.^[155](#fn155){ref-type="fn"}^ This contains a model of EU citizens that imagines them to lack knowledge and be readily distracted by 'science fiction' rather than 'real' issues. Thus, the Nanotechnology Strategy implies a need for public engagement with science in order to focus on regulating societal anxiety and fear, and working with the wider foreclosure of what is 'at stake' and who is regulated into participation. This works to narrow the scope of debate: issues that are not 'of real concern' can thus be designed-out of potential technologies of participation. Nanotechnology innovators (i.e. those scientists and engineers seeking to develop nanoscience and nanotechnology in university and commercial settings) are presumably to be called on within this framework to innovate the shape of public discourse through the separation of the science from the 'science fiction'.

The logics at work here are likewise reflected in the assertion that though the 'Commission is working hard to ensure that nanoscience and nanotechnologies can bring their benefits to the market while controlling their potential risks'. This requires 'significant efforts to *stimulate information sharing and dialogue* among stakeholders to build trust in these technologies'.^[156](#fn156){ref-type="fn"}^ Such comments construct and regulate a rather passive public, designed merely to bring about the dissolution of public concern and the support of pro-innovation regulation.^[157](#fn157){ref-type="fn"}^ In this light, participation can be seen as feeding directly into 'Europe 2020' goals by implicitly promoting the (future) consumption of nano-enabled products and services. In turn, public participation can be read as inter alia a technology to build trust in an uncertain domain of innovation.

Thus, in spite of references to 'dialogue' within EU documents on nanotechnology, this seems to mean a distinctly 'one way' communication of benefit in which public safety concerns are addressed. Arguably, publics need certain information and a level of understanding of the science before an enhanced contribution to regulation and research priority-setting can take place. However, a focus on ignorance and a need for education is problematic. It is supported by PUS initiatives (e.g. the Eurobarometer^[158](#fn158){ref-type="fn"}^) to justify and measure the success of broad educational projects. These techniques also support the notion that publics are in some way being involved in decisions from which they are physically absent. The questions asked are stimulated by anticipatory and promissory discourses, and the fact that responses are given serves to validate these expectations further---reinforcing the need for regulation. However, any 'deficits' in knowledge that the Eurobarometer indicate might also be regarded by some as evidence that more education is required. This might justify a pedagogical element within participatory techniques, further disempowering non-scientists and lending more credibility to expert opinion. From this perspective, technologies of participation can, paradoxically, be understood as deployable as a means of *decreasing* the (substantive) involvement of citizens in regulatory and priority-setting in innovation.^[159](#fn159){ref-type="fn"}^

The current EU model of participation not only potentially underestimates the knowledge of (nano)science and technology that citizens may have, but also reaffirms the technocratic rationalities that exclude them: if publics need to have some kind of expertise in order to be included in deliberation about regulation, some might ask, why not simply limit involvement to credentialed experts in the first place? Part of the explanation is, as suggested above, to do with sharing responsibility and diluting EU accountability. Accordingly, this focus on participation-as-education could be regarded as a counter-democratic move that builds in future obsolescence into the technologies that are produced to elicit and include public perspectives. In other words, the discourses that privilege experts in nanoregulation and power technologies of participation, and which actively seek to reconstitute citizens as such (i.e. to make them expert in some way), eventually renders the technologies themselves redundant (since, if successful, everybody becomes an expert---there is thus no need to consult educated publics since those already working in the nanotechnology field can be taken as having the requisite expertise to help shape regulation).

V.. DISCUSSION {#s5}
==============

In this paper, we have considered the role of public participation in EU regulation of nanotechnology through a novel lens synthesised through insights emerging from law, regulatory studies, critical theory, and STS. Specifically, we have sought to understand participation as a form of technology, and then to highlight both what it does, and some of the norms and values designed into participatory techniques. In so doing, we have sought to cast new light on the ways in which citizens regulate science, and the ways in which they themselves are regulated in the process.

What, then, do technologies of participation do? As should be clear by now, in strict terms of nanoregulation: very little. The EU widely discusses citizen participation in the regulation and governance of technoscientific innovation and implementation, but this is not legally institutionalised. As such participation is a de facto rather than de jure form of governance: it comprises diverse techniques and practices, mandated by policy (i.e. formally non-binding) discourses that are often produced by associated bodies concerned with the implications of technologies (such as the EGE). However, in the case of nanotechnology at least, the actual regulatory power of citizen involvement seems limited. This is surprising given how the wider societal benefits of nanotechnological applications, such as emerging health and medical technologies, are 'talked up' as part of the reason for the EU\'s focus on nanoscience and technology in general and, in relation to that, the figuration of its citizenry. Of course, measuring the impact of participation is an empirical question of the kind which is outside the scope of the more normative analysis this paper has sought to advance. Yet, if citizen participation is a relatively under-utilised and under-powered technology of regulation, what, then is its actual function?

A key role of technologies of participation is to further empower drives to innovate. This is achieved through the instantiation of expectations about the potential of nanotechnology to improve health and wellbeing through applications like emerging health technologies, and within sites, spaces, and fora that can amplify and embed this anticipatory discourse within diverse cultural products (e.g. television shows, radio programmes, film, novels, and newspaper articles). These expectations in turn justify participation (completing the circuit), especially in instances where actual or imagined risks are articulated. In this light, the role of citizen participation in regulation can be seen largely as a means of legitimating (and perhaps even stimulating) innovation through engagement with risk, uncertainty, and promise, and mediating accountability through shared responsibility.

Scientists and engineers are key cogs that turn the wheels of participatory technologies. Their involvement and expertise in nanotechnology implicitly configures 'lay' publics as inexpert, and thus in need of reassuring via education. Such education speaks to modernist values on the import of empirically derived knowledge and the salience of technological 'fixes' for societal 'problems'.^[160](#fn160){ref-type="fn"}^ Innovation thus becomes re-problematised; 'should' and 'how' questions in nanotechnology as a general field come to combined and specified as: how should the science be regulated in order to foster innovation and enhance health, wellbeing, and the economy?

Employing participatory technologies as a means of manufacturing support for innovation aligns regulatory strategies with published EU goals to advance science and produce a knowledge economy built on innovation. In turn, this is an important means through which the heterogeneous assemblage of institutions, agencies, and MSs that constitute 'the' EU produce an identity that represents this as a singular body with aims and the capacity to actualise these (and thus as a powerful and competitive global actor). A focus on innovation for health further legitimates both the EU and those seeking to innovate. It is precisely because these values and sociotechnical imaginaries are 'built into' the policies and practices underpinning and structuring technologies of participation that they function in the way they do.

In sum, then, the EU actively shapes technologies of participation (and hence what they can do) through discourses of risk regulation and bioethics, which are aimed at leveraging uncertainty in scientific knowledge and bringing the future into the present. Supporting this are particular configurations of science/citizen relations (including PUS). Together, these might serve to simultaneously mobilise, prioritise, and include certain hopeful and optimistic, and therefore narrow, publics, that are likely to be underpinned by, and which articulate through, human rights and utilitarian-based ethics. Conversely, the discourses shaping participation might also serve to marginalise and even exclude more pessimistic publics. That is, those individuals and groups that are likely to be underpinned by, and which articulate through, a dignitarian ethic. This renders resort to proceduralism as a means of producing legitimate regulatory decisions in pluralist societies (such as the EU) even more problematic, in that the discourses shaping the conditions of possibility for participation differently empower the perspectives comprising the 'bioethical triangle'. This raises the question: how can legitimate, inclusive, and fair decisions be produced when all voices are implicitly not included, or are marginalised, and remain unheard, because they are in effect designed-out?

Of course, in raising this question and making our broader claims, we do not deny that there may be significant democratic benefits to citizen participation. Rather, it is precisely because of this that we feel it necessary to explore how and why limitations exist. Further, we refuse an account of participatory techniques that figures the citizens that work within them as both lacking in agency and fully configured through the technocratic norms and values that are built into participatory techniques. Indeed, to do so would be to deploy a similar kind of 'deficit model' of citizen engagement to the one that we have been concerned to critique. Thus, our goal here is to suggest that it is the norms, values, and imaginaries constitutive of a genuinely democratic EU, and a body politic comprised of reflexive agents, that need to be more carefully designed and built into technologies of participation. This is antagonistic to current means of inserting publics within restrictive regimes that close down opportunities for dialogue and debate, or which frame these so precisely and narrowly that 'public participation' is less about producing regulatory publics, than publics that are regulated into providing 'public legitimation'.
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